Gyre Therapeutics Inc. (GYRE) — Cash Flow Reinvestment Rate

Latest as of March 2026: 0.96x

Gyre Therapeutics Inc. (GYRE) has a Cash Flow Reinvestment Rate of 0.96x as of March 2026, reinvesting $3.06 Million (capex $178.00K plus investments $-2.88 Million) from operating cash flow of $3.18 Million. See how much free cash does Gyre Therapeutics Inc. generate to measure how efficiently the company converts operating cash flow to free cash.

Reinvestment Rate

0.96x
(Capex + Investments) / Operating CF

Total Reinvested

$3.06 Million
Capex + Investments

Operating Cash Flow

$3.18 Million
USD

Capital Expenditures

$178.00K
USD

Gyre Therapeutics Inc. Cash Flow Reinvestment Rate (2007–2025)

Historical reinvestment intensity for Gyre Therapeutics Inc. across 5 annual periods. For the full cash flow conversion analysis, see GYRE operating cash flow.

Annual Cash Flow Reinvestment Rate for Gyre Therapeutics Inc. (2007–2025)

Year-by-year capital reinvestment analysis for Gyre Therapeutics Inc.. See Gyre Therapeutics Inc. financial flexibility index to measure the company's free cash flow as a share of total liabilities.

Year Reinvestment Rate Total Reinvested (USD) Operating CF Capex YoY Change
2025 2.58x $2.61 Million $1.01 Million $1.19 Million ▲ +136.0%
2023 1.09x $28.35 Million $25.89 Million $8.59 Million ▼ -37.9%
2022 1.76x $18.81 Million $10.68 Million $5.00 Million ▲ +7259.4%
2010 0.02x $3.31 Million $138.30 Million $3.31 Million ▼ -88.0%
2007 0.20x $4.94 Million $24.84 Million $4.94 Million
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow